Zanubrutinib shows safety and efficacy in CLL/SLL patients, regardless of prior ibrutinib treatment, with lower treatment-limiting and cardiac adverse events compared to ibrutinib. The study included ...
Jaypirca significantly improved progression-free survival in treatment-naive CLL/SLL, reducing disease progression or death risk by 80% compared to BR. The 24-month progression-free survival rate was ...
Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...
(ORLANDO, Dec. 9, 2025) – In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more ...
Abbvie ((ABBV)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded ...
Retrospective ONCare Alliance Network data showed lower odds of new or worsened hypertension with acalabrutinib versus ibrutinib (OR 0.27; 95% CI, 0.074–0.98). Despite older age and higher baseline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results